B2BROKER
8.2.2024 09:28:35 CET | Business Wire | Press release
B2Broker, a global powerhouse of liquidity and technology in the B2B sector for crypto, Forex and financial sectors, has partnered with Tools for Brokers (TFB), which provides elite solutions to brokers, liquidity providers, prop trading agencies and hedge funds.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208106794/en/
B2Broker partners with Tools for Brokers to integrate Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides. (Graphic: Business Wire)
B2Broker aims to integrate TFB’s Trade Processor liquidity bridge into its existing ecosystem, enhancing the flexibility and efficiency of liquidity services it provides.
Importance of B2Broker and TFB Partnership
This collaboration combines B2Broker’s robust liquidity services with TFB’s cutting-edge Trade Processor technology. Here’s what you can expect from the partnership:
Enhanced Risk Mitigation - Trade Processor liquidity gateway introduces the trade routing feature that significantly elevates risk management capabilities for B2Broker clients. The platform can also provide advanced trade routing solutions to retail brokers with their MT4/MT5 servers. Traders can also seamlessly switch between A-Book and B-Book, increasing their flexibility and ability to adapt to market trends.
Elevated Access - With this integration, B2Broker clients will seamlessly access MT4, MT5 and cTrader platforms. The external FIX API integration is also possible for connecting third-party platforms.
Intuitive UI and Advanced Analytics - the Trade Processor also streamlines the digital user interface, making it easy to obtain essential data and access B2Broker’s features. The trading History page now overviews closed positions and all relevant details. Additional pages allow clients to analyse open position stats and exposure metrics and monitor the server performance.
Arthur Azizov, CEO of B2Broker, shared his thoughts on the partnership: "Our collaboration with Tools for Brokers directly supports our goal to deliver innovative technology to clients. TFB's Trade Processor upgrades our offerings with improved risk management and seamless integration across major trading platforms. At the same time, this partnership opens up B2Broker's extensive liquidity pool of over 800 pairs across eight asset classes to TFB users. It’s a mutual exchange of strengths that promises to enhance the value we, B2Broker and TFB, aim to deliver to our clients."
Alexey Kutsenko, the CEO at Tools for Brokers, outlined his excitement for the upcoming collaboration: “We are excited to partner with B2Broker. The company is well-known for its powerful ecosystem of products for brokers. I am confident that together we will create an even stronger solution for B2Brokers’ clients and help them grow faster and stay resilient.”
About Tools for Brokers
Tools for Brokers (TFB) is a global tech provider that serves retail brokers, LPs, prop trading firms and hedge funds operating on multiple platforms like MT4, MT5, Match-Trader and cTrader. TFB’s solutions are powered by their cutting-edge Trade Processor liquidity bridge. The core technology is further elevated by data analytics, risk mitigation tools, money management solutions and a single digital hub to manage TFB plugins effortlessly.
For more information, visit www.t4b.com
B2Broker’s Services
B2Broker is a global leader in the liquidity and fintech sector. B2Broker provides B2B services to forex brokers, crypto exchange platforms, prop traders, crypto spot brokers, multi-asset brokers and many other industries. B2Broker offers over 800 liquidity instruments supported by eight different asset classes. Moreover, the platform features payment processing solutions, white-label solutions, back-office, and numerous other mechanisms to create a full-stop liquidity and business management service for their B2B clients.
For more information, visit b2broker.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240208106794/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom